You are here

  • Home
  • Archive
  • Volume 71, Issue 2
  • Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?

Article Text

Article menu
Download PDFPDF
HOT off the breath
Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?

https://doi.org/10.1136/thoraxjnl-2015-207854

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests SDN has consulted for, is on the speaker’s bureau and received research funding from the sponsor of the AMBITION study, Gilead Pharmaceuticals. PAC has received research grant funding from Bayer and Actelion and sat on remunerated advisory boards for Bayer, Actelion and GSK.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • Airwaves
      Highlights from this issue
      Nicholas Hart Gisli Jenkins Alan Smyth
      Thorax 2016; 71 i-i Published Online First: 14 Jan 2016. doi: 10.1136/thoraxjnl-2015-208244